Previous 10 | Next 10 |
Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at a new 52-week low of $4.11. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. In the past 52 weeks, Assembly Biosciences Inc. share prices are bracketed...
Assembly Biosciences, Inc. (ASMB) Hepatitis B Program Update Conference Call February 25, 2021 5:00 PM ET Company Participants Lauren Glaser - Senior Vice President of Investor Relations and Corporate Affairs John McHutchison - President and Chief Executive Officer Bill Delaney - Chief Scient...
Assembly Biosciences (ASMB) and Arbutus Biopharma (ABUS) have initiated a Phase 2 clinical trial of Assembly Bio’s investigational capsid inhibitor, vebicorvir ((VBR)), in combination with Arbutus’ GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos...
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasd...
Assembly Biosciences (ASMB): FY GAAP EPS of -$1.75 misses by $0.19.Revenue of $79.1M (+395.6% Y/Y) misses by $2.91M.Press Release For further details see: Assembly Biosciences EPS misses by $0.19, misses on revenue
Assembly Biosciences (ASMB) announced that it is foregoing plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy ((CST)) to concentrate its research and development efforts on finite and curative HBV therapies.The decision co...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the fourth quarte...
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call toda...
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events: 2021 Key Objectives ...
Assembly Biosciences (ASMB) has announced to wind-down its microbiome program, enabling the company to prioritize resources and focus on hepatitis B virus programs.While Assembly Bio will continue its ongoing review of potential strategic options for the microbiome program in the interim...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...